KDM1B Knockout NCI-H1975 Polyclonal Cells are a polyclonal population of NCI-H1975 human lung adenocarcinoma cells engineered via CRISPR/Cas9 to disrupt the KDM1B gene, resulting in a heterogeneous loss-of-function model. This polyclonal knockout pool preserves the genetic diversity inherent to the CRISPR/Cas9 editing process, enabling the study of KDM1B deficiency in a mixed cellular context that more closely mimics tumor heterogeneity.
The NCI-H1975 parental cell line is a well-characterized human non-small cell lung cancer (NSCLC) epithelial model, originally derived from a female patient with adenocarcinoma. These cells harbor activating EGFR L858R and T790M mutations, which drive oncogenic signaling and confer resistance to first-generation tyrosine kinase inhibitors. The cell line is widely employed to investigate mechanisms of EGFR-dependent proliferation, survival, and drug resistance.
KDM1B (lysine-specific demethylase 1B) is a histone H3 lysine 4 (H3K4) demethylase that specifically removes mono- and dimethyl marks (H3K4me1/me2), a key epigenetic modification at enhancers and promoters. It functions within a multi-protein complex that includes the co-repressor RCOR2 (CoREST2), histone deacetylases HDAC1/2, and the host cell factor HCFC1. KDM1B is transcriptionally regulated by upstream signals such as NOTCH1 intracellular domain, MYC, and TGF-?? pathways, and it modulates downstream targets including HOX gene clusters, the pluripotency factors NANOG and OCT4, and broader stemness-associated transcriptional programs. Disruption of KDM1B alters H3K4 methylation landscapes, thereby modulating chromatin accessibility and gene expression involved in development, cellular differentiation, and tumorigenesis.
In the context of NCI-H1975 NSCLC cells with EGFR T790M/L858R mutations, KDM1B knockout provides a powerful system to dissect epigenetic contributions to oncogene addiction and drug tolerance. Loss of KDM1B-mediated demethylation may shift H3K4me1/me2 patterns and perturb the expression of genes linked to WNT, NOTCH, and TGF-?? signaling cascades, potentially impacting EGFR-driven proliferation and resistance mechanisms. The polyclonal nature of the knockout population further allows the modeling of tumor cell heterogeneity that influences adaptive responses to targeted therapies such as gefitinib or osimertinib.
This knockout model is suited for advanced functional genomics studies, including RNA-seq and ChIP-seq analyses to map KDM1B-dependent transcriptional and epigenomic changes, and co-immunoprecipitation to characterize interacting protein complexes. It enables targeted investigation of KDM1B??s role in histone methylation dynamics, stem cell-like properties, and drug sensitivity. Assays such as Western blot for H3K4 methylation status, cell viability and apoptosis assays, migration and invasion tests, and colony formation can be integrated. Researchers can utilize these polyclonal cells for epigenetic drug screens or to elucidate mechanisms of resistance in EGFR-mutant lung adenocarcinoma. For additional technical information or custom inquiries, please contact Ascent Research.
